Posted 27th March 2020 by Joshua Sewell
This article is republished with kind permission from BioVox.
Augustine Therapeutics is one of VIB’s latest spinoffs, developing a first-in-class drug for Charcot-Marie-Tooth disease. The company recently announced a seed-funding round of €4.2 million, led by V-Bio Ventures. We spoke to several of the key persons in Augustine about how the startup is tackling the “Valley of Death”: the no-man’s-land between academia and industry where many potential therapies often fail.
Posted 8th May 2019 by Joshua Sewell
Microbiome research is abundant and profoundly inspiring. Whether focusing on cancer drug response, or the more classical field of gut discomfort solutions, we are clearly on the brink of some long-anticipated breakthroughs. But despite the promise, companies in the field face challenges.
Posted 27th April 2018 by Jane Williams
The blockchain technology market is expected to grow to 2.3 billion US dollars by 2021, from 339.5 million US dollars in 2017.  With an annual growth rate of 61.5%, it is one of the fastest growing technologies in the healthcare industry.